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Abstract
Purpose: A meta-analysis was conducted to evaluate the impact of oral multitargeted kinase inhibitors (MTKIs) in 
radioactive-iodine refractory locally advanced, recurrent/metastatic differentiated thyroid cancer (DTC) on disease 
control rate (DCR), progression-free survival (PFS) and overall survival (OS) rates.
Materials and Methods: The PubMed/MEDLINE, CANCERLIT, EMBASE, Cochrane Library database and other 
search engines were searched to identify randomised controlled trials (RCTs) comparing MTKIs with placebo in 
locally advanced, recurrent/metastatic DTC. Pooled data were expressed as odds ratio (OR), with 95% confidence 
intervals (CIs, Mantel–Haenszel fixed-effect model).
Results: Three RCTs with a total patient population of 954 patients were identified. The use of MTKIs was associated 
with improved PFS (OR: 0.262, 95% CI: 0.19–0.35; heterogeneity (I2) = 22.4%; P < 0.0001), improved DCR (complete 
and partial responses + stable disease, P < 0.0001) and improved OS 0.66, 95% CI: 0.46–0.96 (I2 = 43%, P = 0.034). 
Lenvatinib (compliance = 87%) was associated with more grade ≥3 hypertension. However, its other adverse effects 
were much lower than sorafenib (compliance = 56%) and vandetanib.
Conclusion: In radioactive iodine-refractory recurrent, metastatic DTC patients, lenvatinib and sorafenib were 
associated with improved PFS, DRC and OS rates, while the compliance was better with lenvatinib.
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Introduction
Differentiated thyroid cancers (DTC), which include 
papillary, follicular and poorly differentiated subtypes, 
constitute 90% of all thyroid malignancies.[1] DTC has 
generally an excellent outcome after the traditional 
treatment which includes surgery, thyroid-stimulating 
hormone suppression therapy and radioactive iodine (RAI) 
therapy and, in some cases, radiation therapy.[1] Despite 
this, 10%–25% of DTC patients experience locoregional 
recurrence and distant metastasis which need additional 
treatment measures in the form of surgery or RAI for 
cure or significant palliation.[2] Patients with iodine-avid 
recurrent or metastatic disease from DTC may continue 
to receive multiple sessions of RAI. Subsequently, 
about two-thirds of such patients become refractory to 
RAI uptake.[3] Systemic chemotherapy has been found 
relatively ineffective with poor response rates (10%–
37%) and has shown to be associated with significant 
toxicities.[4]
During the past decade, aberrant signaling pathways 
have been investigated in the development, progression 
and metastasis of DTC such as BRAF and RAS 
point mutations and rearrangement of the RET proto-
oncogene in papillary cancers; RAS point mutations and 
rearrangement of the peroxisome proliferator-activated 
receptor gamma (PPARG) and PAX8 genes in follicular 
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cancers and RAS point mutations, endothelial growth 
factor receptor, vascular endothelial growth factor 
receptor (VEGFR) overexpression and PIK3CA in poorly 
differentiated cancers.[5] Identification of these potential 
targets has led to the development of novel multitargeted 
kinase inhibitors (MTKIs) for RAI-refractory recurrent, 
metastatic DTC.[6,7] However, efficacy, safety profile and 
impact on treatment outcome by MTKIs have not been 
well studied in DTC patients.
We conducted a meta-analysis to assess the impact of 
MTKIs in RAI-refractory, locally advanced, recurrent, 
metastatic DTC on progression-free survival (PFS), 
disease control rate (DCR), toxicity profile and overall 
survival (OS).
Materials and Methods
Studies and study population
Eligible studies had to be either complete reports of 
prospective, randomised controlled trials (RCTs) or 
well-controlled retrospective studies. The abstracts 
from which full details were available were also 
included. The PubMed/MEDLINE, CANCERLIT, 
EMBASE, Cochrane Library database, Web of Science, 
Academic Search Premier and CINAHL were searched 
(period 2000–2015) using the terms “(thyroid cancer, 
DTC, carcinoma), (papillary, follicular, poorly DTC, 
carcinoma), (tyrosine kinase inhibitors, MTKIs, 
Sorafenib, Sunitinib, Axitinib, Motesanib, Vandetanib, 
Pazopanib, Lenvatinib), the efficacy and safety”. These 
terms were then combined to search for eligible studies. 
The relevant articles were selected by two investigators. 
Only studies that met the following criteria were included 
[Figure 1] shows flow diagram of the meta-analysis.
Inclusion criteria were (a) histologically confirmed DTC 
(papillary, follicular and poorly differentiated cancers), (b) 
RAI-refractory recurrent or metastatic DTC and (c) treated 
with oral MTKIs as monotherapy. Patients with DTC 
who received antiangiogenic drugs other than MTKIs or 
histone deacetylase inhibitors, PPARG agonists, retinoid 
receptor agonists and proteasome inhibitors were excluded 
from the study. Table 1 shows the prospective randomised, 
phase II/III trials in refractory DTC with MTKIs included 
in this review. Table 2 shows the application of inclusion 
and exclusion criteria.
Outcome measures and review analysis
The outcome measures were PFS, DCR, toxicity profile and 
OS. All analyses were carried out on an intention to treat 
analysis basis. For the categorical variables, weighted odds 
ratios (ORs) and their 95% confidence intervals (95% CI) 
were calculated. The results were tested for heterogeneity 
(I2) using Cochran’s Q-test at the significance level of P 
< 0.05. If there was evidence of heterogeneity, a random 
effect model was used for meta-analysis; otherwise, 
fixed effect model was used. The OR and 95% CI were 
calculated for each RCT and presented in forest plot. The 
DCR was defined as complete response + partial response 
Figure 1: Flow diagram of meta-analysis
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+ stable disease based on Response Evaluation Criteria in 
Solid Tumours criteria and follow-up period mentioned in 
each RCT. Publication bias was evaluated using the funnel 
graph, the Begg–Mazumdar adjusted rank correlation test[8] 
and the Egger test.[9] All analyses were performed using 
comprehensive meta-analysis software version 3.3.070.
Results
The electronic search revealed 23,204 relevant citations, 
of which 352 were selected. Finally, three RCTs were 
identified that fulfilled the criteria.Figure 5: Funnel plot of publication bias
Figure 2: Forest plot for progression-free survival
Figure 3: Forest plot for disease control rate
Figure 4: Forest plot for overall survival
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PFS
All three RCTs with a population of 954 patients analysed 
the PFS rate as one of the outcomes. PFS rates were 
significantly higher in patients treated with MTKIs, 
especially lenvatinib and vandetanib (P < 0.0001). The 
pooled OR was 0.262 (95% CI: 0.19–0.35; I2 = 22.4%) 
[Figure 2].
DCR
Two RCTs with 809 patients examined the DCR as one of 
the outcomes. MTKIs, especially lenvatinib, were associated 
with significantly higher DCR (P < 0.0001) [Figure 3].
OS
All three RCTs, with 954 patients, addressed the OS as one 
of the outcomes. Two RCTs of sorafenib and lenvatinib 
showed a significant improvement in the OS, while one 
RCT of vandetanib showed no survival benefit. The pooled 
OR was 0.66, 95% CI: 0.46–0.96 (I2 = 43%, P = 0.034) 
[Figure 4].
Toxicity profile
All three TCTs with 954 patients reported the toxicities, 
dose reductions and compliance as one of the outcomes. 
Lenvatinib (compliance = 87%) was associated with more 
Grade 3 hypertension; however, other adverse effects 
were much lower than sorafenib (compliance = 56%) and 
vandetanib (compliance not reported) Table 3.
Publication bias
The resultant funnel plot was significantly narrower with 
statistical significance by Egger test of P = 0.05 Figure 5.
Discussion
In the present meta-analysis, the pooled analysis showed 
that MTKIs (lenvatinib, sorafenib and vandetanib) 
significantly improve the PFS and DCR rates, in 
RAI-refractory DTC patients. Further, lenvatinib and 
sorafenib showed a trend of increased OS rates. Past 
experience obtained from using MTKIs has shown that 
the adverse effects associated with VEGFR inhibition 
include hypertension, proteinuria, delayed wound healing, 
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present meta-analysis, the incidence of severe hypertension 
was much higher with Lenvatinib, which warrants its use 
with extreme caution in hypertensive patients. On the 
other hand, sorafenib resulted in more Grade 3 ≥hand-
foot syndrome and vandetanib resulted in significant QTc 
prolongation. Possible explanation for relatively higher 
adverse effects in DTC patients as compared to patients of 
Table 2: Inclusion and exclusion criteria of included studies in meta‑analysis
Study Mean age Inclusion criteria Exclusion criteria Previous therapy Definition of DCR
Leboulleux, 
et al.[10]
‑ Aged ≥18 years, with 
locally advanced/
metastatic refractory 
DTC (papillary, follicular 
or poorly differentiated) 
Prior targeted ther‑
apy, thalidomide or 
chemotherapy
RAI ablation A CR or PR or 
durable SD 
for ≥23 weeks
DECISION trial[11] 63 years Aged ≥18 years, with 
locally advanced/
metastatic refractory 
DTC (papillary, follicular 
or poorly differentiated)
Prior targeted ther‑
apy, thalidomide or 
chemotherapy
RAI ablation A CR or PR or 
durable SD 
for ≥23 weeks
SELECT trial[12] 64 years Aged ≥18 years with 
locally advanced, meta‑
static refractory DTC, at 
least one measurable 
lesion without iodine
uptake on any io‑
dine‑131 scan
Prior target‑
ed therapy or 
chemotherapy
RAI ablation within 
12 months 
A CR or PR or 
durable SD 
for ≥23 weeks
DTC: Differentiated thyroid cancer, DCR: Disease control rate, CR: Complete response, PR: Partial response, SD: Stable disease, 
RAI: Radioactive iodine
Table 3: Incidence of toxicity profile ≥Grade 3 in included studies in meta‑analysis
Adverse effects Vandetanib (%) Sorafenib (%) Lenvatinib (%)
Hypertension ‑ 20 41.8
Diarrhoea 10 11 8.0
Fatigue 12 11 9.2
Hand‑foot syndrome ‑ 42 3.4
Proteinuria ‑ ‑ 10
Pulmonary embolism ‑ ‑ 2.7
Dyspnoea ‑ 10 ‑
Decreased appetite ‑ ‑ 5.4
Sensory neuropathy ‑ 2 ‑
Skin/desquamation ‑ 10 ‑
Abdominal pain ‑ 3 ‑
QTc prolongation 14 ‑ 1.5
Pneumonia 1.5 ‑ ‑
Thromboembolic events ‑ ‑ 3.8
renal and hepatocellular cancers treated by similar MTKIs 
could be the prior multiple RAI sessions or high RAI 
cumulative dose, which suggests possible radiosensitising 
effects of MTKIs;[16] however, future Phase I and II trials 
can give answers by the use of MTKIs in RAI naïve DTC 
patients. Patient-related compliance was significantly 
higher with lenvatinib. In contrast to present meta-
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analysis, previous meta-analysis which was conducted 
by Hesselink et al. was criticised mainly for two reasons 
(a) primary objective was limited only to response rates 
and (b) medullary carcinoma of thyroid was not excluded 
to see absolute benefit of MTKIs in DTC; however, this 
study concluded that MTKIs in thyroid cancer show a 
modest response rates; among MTKIs, response rates were 
promising with Lenvatinib and Vandetanib.[17]
The strengths of our meta-analysis were (1) completeness 
of the search strategy, including searching multiple 
databases, trial registries and conference proceedings for 
RCTs comparing MTKIs to the placebo group in RAI 
refractory locally advanced/metastatic DTC patients; 
(2) DCR rates and (3) evaluation of the PFS and OS 
benefit and toxicity profile of MTKIs. The limitations of 
our meta-analysis were (1) inherent methodological issues 
in the included trials (risk of bias), (2) attrition bias and 
(3) reporting bias in included RCTs.
Conclusion
In view of this meta-analysis and magnitude of the 
problem of RAI-refractory recurrent, metastatic DTC and 
efficacy and safety of MTKIs, lenvatinib and sorafenib 
were associated with improved PFS, DRC and OS rates, 
while the compliance was better with lenvatinib. However, 
oncologists and endocrinologists should be aware of 
proper case selection, adverse effects and precautions, 
nursing care and frequent follow-ups to improve quality of 
life and reduce morbidity and mortality in these patients.
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